SCLP Share Price Performance
UK£0.10
0.00 (2.05%)
61.0% undervalued intrinsic discount
UK£0.26
Fair Value
Price UK£0.10
AnalystConsensusTarget UK£0.26
AnalystLowTarget UK£0.19
Fair ValueUK£0.26
Share Pricen/a
New Narrative • Jul 26
Scancell Holdings plc Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
SCLP Community Narratives
AN
Fair Value
·Fair Value UK£0.26 61.0% undervalued intrinsic discount
Cancer Immunotherapies Will Benefit From Growing Checkpoint Inhibitor Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value UK£0.19 47.6% undervalued intrinsic discount
Phase III Funding Delays And Cash Burn Will Test Long-Term Cancer Immunotherapy Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Cancer Immunotherapies Will Benefit From Growing Checkpoint Inhibitor Adoption
Scancell is pushing its cancer treatments toward late-stage testing as more doctors use checkpoint inhibitor drugs, which could make its therapies attractive add-ons. But the company is still burning cash and needs trials, partners, and funding to fall into place for the story to work.Read more
AN
UK£0.26
61.0% undervalued intrinsic discount
Fair Value
Profit Margin
17.55%
Future PE
5.14kx
Price in 2029
UK£0.32
Phase III Funding Delays And Cash Burn Will Test Long-Term Cancer Immunotherapy Potential
Scancell aims to bring a cancer treatment for advanced melanoma into a late-stage trial, but it still needs money or a partner to run it, and any delay could shrink the window to benefit if it works. The bigger question is whether its wider pipeline and partner deals can keep the company funded long enough to reach the point where a real product launch becomes possible.Read more
AN
UK£0.19
47.6% undervalued intrinsic discount
Fair Value
Profit Margin
17.55%
Future PE
3.51kx
Price in 2029
UK£0.24
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Phase III Funding Delays And Cash Burn Will Test Long-Term Cancer Immunotherapy Potential
Fair Value: UK£0.19 47.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SCLP: Fast Track Status And Nasdaq Path Will Support Bullish Outlook
Fair Value: UK£0.26 61.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Scancell Holdings plc Key Details
Last Reported Earnings
Oct 31, 2025
Next Reporting Earnings
n/a
- -0.0045
- 94.95%
- -116.98%
- -189.5%
About SCLP
- Founded
- 1996
- Employees
- 60
- CEO
- WebsiteView website
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
